Conjugated pneumococcal vaccine versus polysaccharide pneumococcal vaccine for prevention of pneumonia and invasive pneumococcal disease in immunocompetent and immunocompromised adults and children

Miri Golos, Noa Eliakim-Raz, Anat Stern, Leonard Leibovici, Mical Paul*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: The primary objective is to compare the effects of pneumococcal conjugated vaccines (PCV) alone or added to a pneumococcal polysaccharide vaccine (PPSV) versus PPSV alone for the prevention of any pneumonia. Secondary objectives are: to compare the effect of PCV versus PPSV vaccine on any IPD and IPD caused by VT serotypes; to compare the effect of PCV versus PPSV vaccine on VT pneumonia and any pneumonia requiring hospitalisation; to examine the effects of PCV versus PPSV on immunological outcomes (antibodies level; opsonophagocytic activity); to compare the effect of PCV versus PPSV on serotype replacement; and to compare the adverse events caused by PCV to the adverse events caused by PPSV.

Original languageEnglish
Article numberCD012306
JournalCochrane Database of Systematic Reviews
Volume2016
Issue number8
DOIs
StatePublished - 4 Aug 2016
Externally publishedYes

Fingerprint

Dive into the research topics of 'Conjugated pneumococcal vaccine versus polysaccharide pneumococcal vaccine for prevention of pneumonia and invasive pneumococcal disease in immunocompetent and immunocompromised adults and children'. Together they form a unique fingerprint.

Cite this